Company Declares Up to $0.15 Per Share Shareholder Loyalty Payment
In additional to the interim dividend, the Board has declared a one-time shareholder loyalty payment of up to $0.15 per share under its newly approved Shareholder Loyalty Program. Eligible shareholders who transfer their shares into book-entry form with the Company's transfer agent on or prior to the loyalty program start and record date of December 29, 2025, will receive up to three tranches of loyal payments if they maintain continuous ownership for 30 to 90 calendar days thereafter, payable in cash as following: Such eligible shareholders who maintain their book entry with the Company's transfer agent for first 30 calendar days of the loyalty period will receive $0.05 in cash, payable as soon as practical after expiration of such 30-day period; Such eligible shareholders who maintain their book entry with the Company's transfer agent for first 60 calendar days of the loyalty period will receive an additional $0.05 in cash, payable as soon as practical after expiration of such 60-day period; and Such eligible shareholders who maintain their book entry with the Company's transfer agent for full 90 calendar days of the loyalty period will receive an additional $0.05 in cash, payable as soon as practical after expiration of such 90-day period. The enrollment and election period will be running from December 29, 2025 to March 28, 2026, and the loyalty payment expected to be distributed on or about the 15th day after the expiration of each 30-day tranche. Insiders, including officers, directors, and employees of the Company, are not eligible to participate in the Shareholder Loyalty Program.
Get Free Real-Time Notifications for Any Stock
Analyst Views on FTEL
About FTEL
About the author

Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%
- Significant Stock Surge: Cyclerion Therapeutics shares rose 44.2% to $1.99 in pre-market trading, reflecting strong market confidence in the company's expanded strategic collaboration with Medsteer, indicating positive investor sentiment towards future growth prospects.
- Deepening Strategic Collaboration: The partnership with Medsteer aims to advance the closed-loop anesthetic platform CYC-126, which is expected to accelerate the product's market entry, thereby enhancing the company's competitive edge in the anesthesia sector.
- Optimistic Market Outlook: With continuous advancements in anesthetic technology, Cyclerion's new platform is poised to meet the increasing medical demand, further driving revenue growth and strengthening its position in the healthcare industry.
- Increased Investor Confidence: The substantial stock price increase not only reflects market approval of the company's strategic direction but may also attract more investor interest, thereby supporting future financing and expansion efforts.

Fitell Corporation Implements 1-for-8 Share Consolidation to Optimize Capital Structure
- Share Consolidation Plan: Fitell Corporation will implement a 1-for-8 share consolidation on January 8, 2026, reducing outstanding Class A shares from 9,666,791 to 1,208,349 and Class B shares from 402,500 to 201,250, thereby optimizing its capital structure to support future growth.
- Market Trading Arrangement: Post-consolidation, Class A shares will continue trading on Nasdaq under the new CUSIP number G35150146, ensuring a seamless transition for investors at market open and enhancing market liquidity.
- Shareholder Approval and Decision: The share consolidation was approved at the shareholders' extraordinary general meeting on December 12, 2025, with the board confirming the consolidation ratio via written resolutions on December 16, demonstrating transparency and efficiency in corporate governance.
- Future Strategic Positioning: CEO Sam Lu stated that the strengthened equity profile will provide greater flexibility for future strategic partnerships, acquisitions, or other capital market activities, enhancing the company's competitive position within the industry.









